MiMedx Group, Inc. (NASDAQ:MDXG) Insider Kimberly Maersk-Moller Sells 1,759 Shares

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 1,759 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.04, for a total value of $14,142.36. Following the completion of the sale, the insider now directly owns 309,077 shares in the company, valued at approximately $2,484,979.08. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Thursday, March 13th, Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock. The shares were sold at an average price of $7.89, for a total value of $32,396.34.
• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The shares were sold at an average price of $8.40, for a total value of $17,732.40.

MiMedx Group Trading Down 1.5 %

Shares of MDXG opened at $7.97 on Friday. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.49 and a beta of 1.97. The stock’s 50-day moving average price is $8.39 and its 200 day moving average price is $7.84.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds have recently bought and sold shares of MDXG. IMG Wealth Management Inc. acquired a new stake in MiMedx Group in the 4th quarter valued at about $28,000. Virtus Fund Advisers LLC acquired a new stake in MiMedx Group in the 4th quarter valued at about $35,000. Van ECK Associates Corp acquired a new stake in MiMedx Group in the 4th quarter valued at about $40,000. Point72 DIFC Ltd lifted its stake in MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in MiMedx Group by 77.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.